BerGenBio ASA
BRRGF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -4,502.77% | -9,284.95% | -21,564.74% | -21,298.80% |
| EV / EBITDA | 1.01 | 0.81 | 0.49 | 1.41 |
| Quality | ||||
| ROIC | -122.44% | -149.98% | -344.29% | -81.46% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.10 | 1.18 | 0.95 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.66% | -22.95% | -13.50% | -55.70% |
| Free Cash Flow Growth | 31.92% | 21.90% | 4.98% | -29.44% |
| Safety | ||||
| Net Debt / EBITDA | 1.04 | 0.82 | 0.50 | 1.41 |
| Interest Coverage | -32.18 | -331.87 | -952.13 | -5,933.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 292.26 | 725.88 | 638.05 | 683.79 |